Vivani to merge subsidiary Cortigent with ClearOne in Nasdaq listing deal

Corporate ActionM&A · Partnership
โดย GlobeNewswire·Read original
Summary · why it matters

Vivani Medical has entered into a definitive merger agreement under which its wholly owned subsidiary Cortigent will become a wholly owned subsidiary of Nasdaq-listed ClearOne, with the combined company to be renamed Cortigent Holdings and trade under the ticker CRGT. ClearOne has agreed to raise between $10,000,000 and $15,000,000 in a concurrent financing. Vivani will receive 12,500,000 shares of ClearOne common stock and is expected to own 59.4% to 67.5% of the combined company, while former ClearOne shareholders will own 12.7% to 14.4%. The transaction, unanimously approved by both boards, is expected to close in the third quarter of 2026, subject to stockholder approvals, completion of the financing, and continued Nasdaq listing. Cortigent develops brain-computer interface devices based on precision neurostimulation technology, including the Orion artificial vision system and a device to aid arm and hand recovery after stroke.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 1 stocks
Vivani Medical Inc.
VANI
▲ PositiveCapitalrelevance

Vivani will receive 12.5M shares of ClearOne and own majority of combined company, unlocking value from its subsidiary.

Information Technology▲ · 1 stocks
ClearOne Inc
CLRO
± MixedCapitalrelevance

ClearOne is being acquired by Cortigent, with a concurrent financing and stock issuance; impact depends on deal terms and future prospects.

Theme Impact 1

Off-coverage companies 1

Cortigent HoldingsPrivate▲ Positive
Capitalrelevance

Cortigent becomes a Nasdaq-listed entity via merger with ClearOne, gaining public market access and financing.

Related news

Onward Medical H1 2026 Revenue Surges 250% as ARC-EX Sales Top 159 Systems

Onward Medical reported H1 2026 revenue of EUR4.2 million, up 250% year-over-year, with EUR3.4 million coming from product revenues and gross profit of EUR2.9 million at roughly 70% gross margin. The company sold or supplied 159 ARC-EX systems via paid evaluation in H1 2026, more than a 5x increase year-over-year, including 89 units sold in Q2 2026 alone, with the device now available in over 150 clinics worldwide, including over 130 in the US, covering an estimated 35-40% of US facilities managing spinal cord injury. Operating expenses rose to EUR26.3 million from EUR21 million in H1 2025, producing an operating loss of EUR23.3 million and a net loss of EUR24.7 million, while cash burn reached EUR26 million. The company ended June 2026 with EUR81.5 million in cash, up from EUR68.1 million at the start of the year, after raising over EUR40 million in new equity capital including EUR25 million from EQT Life Sciences, and secured a debt facility of up to EUR50 million from BlackRock replacing its existing loan, with EUR20 million drawn at closing, extending its cash runway into Q1 2028. On the clinical side, the EMPOWER-BP pivotal trial has enrolled 22 participants across 14 active sites, with interim analysis expected by end of Q1 or early Q2 2027, and the company completed its CMS coding submission with a decision expected in Q4 2026.
BLKRTX
Brain-Computer Interface
GuruFocus·7dRead more →
▲

NeuroPace Beats Q2 Estimates, Raises 2026 Revenue Guidance to $99.5-$101.5 Million

NeuroPace reported a second-quarter 2026 loss per share of 18 cents, beating the Zacks Consensus Estimate by 5.3% and improving from a loss of 30 cents a year earlier. Revenue rose 17.1% year over year to $22.8 million, led by the RNS System, whose revenues totaled $22.5 million, up 21.3%, while service revenues fell to $302,000 from $937,000 a year ago following the DIXI Medical wind-down. Adjusted gross margin contracted 60 basis points to 83.4%, and the adjusted operating loss narrowed to $2.8 million from $5 million. Management raised full-year 2026 revenue guidance to $99.5-$101.5 million from $99-$101 million, reflecting expected service revenues of about $1 million, up from roughly $500,000 previously, while the RNS revenue growth outlook remains 21%-23%. The company also lifted its adjusted gross margin outlook to 82%-83% and narrowed its expected adjusted EBITDA loss to $7.5 million-$8.5 million, though consensus estimates have trended downward over the past month.
NPCE ▲
Brain-Computer Interface ▲
Zacks Investment Research·8dRead more →
▲

Brain Implants Market to Reach USD 18.39 Billion by 2035, Growing at 9.99% CAGR

The global brain implants market is projected to grow from USD 7.10 billion in 2025 to USD 18.39 billion by 2035, expanding at a compound annual growth rate of 9.99 percent, according to a new report by SNS Insider. North America held the largest share in 2025, with the U.S. market alone valued at approximately USD 3.16 billion and expected to reach USD 8.17 billion by 2035. The deep brain stimulators segment accounted for about 37.6 percent of total revenue in 2025, while Parkinson's disease represented the largest application segment at roughly 34.3 percent. The Asia-Pacific region is forecast to be the fastest-growing market, driven by rising neurological disease prevalence and expanding neurosurgical infrastructure.
Brain-Computer Interface ▲
GlobeNewswire·83dRead more →
© 2026 MarketDXNews